Prosthesis type has minimal impact on survival after valve surgery in patients with moderate to end-stage renal failure.

Department of Cardiothoracic Surgery, Mount Sinai School of Medicine, New York, NY 10029, USA.
Nephrology Dialysis Transplantation (Impact Factor: 3.37). 08/2008; 23(11):3613-21. DOI: 10.1093/ndt/gfn337
Source: PubMed

ABSTRACT Few previous studies have reported on the outcome of patients with renal failure (RF) undergoing valvular surgery, particularly with regard to choice of valve prosthesis.
We retrospectively analyzed prospectively collected data from 155 patients with RF (mean age 62 +/- 14, 42% female) who underwent left-sided valve surgery from January 1998 to December 2006. Patients were divided into two groups: Group 1 (non-dialysis-dependent renal failure (NDRF); creatinine >2.5 mg/dl; n = 47, 40%) and Group 2 (renal failure dialysis (DRF); n = 108, 60%). Mechanical valves were implanted in 50 (32%) patients and bioprostheses in 63 (41%). Isolated mitral valve reconstruction was performed in 27% (n = 42) of patients. Outcome measures included hospital mortality, major postoperative complications, length of hospital stay, discharge planning and late survival.
The overall hospital mortality was 19.3% (n = 30) and was not different between Groups 1 (23%) and 2 (18%). Ejection fraction, peripheral vascular disease, aortic valve replacement and reoperation were independent predictors of hospital mortality. One- and five-year survival rates were 74.4 +/- 7.8% and 53.1 +/- 10.1% in Group 1 and 75.8 +/- 4.6% and 49.1 +/- 7.1% in Group 2 (P = ns), respectively. According to the type of prostheses, hospital mortality and freedom from reoperation were similar in patients with mechanical and biological valves. Five-year survival rate was 51 +/- 10.7 for biological valves versus 55 +/- 8.4 for mechanical valves (P = ns).
Hospital mortality and morbidity remain high in patients with RF undergoing valvular surgery and it is not different in NDRF and DRF patients. This study suggests that the type of valve prosthesis does not appear to have an impact on early and late survival but is limited by sample size. It may be that bioprostheses should be more widely used in patients with RF requiring valve replacement.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The objective of this study was to assess short-term and long-term outcomes after valve replacement with biologic or mechanical prostheses in patients with preoperative end-stage renal disease on chronic dialysis. A retrospective review of patients with end-stage renal disease undergoing valve replacement from January 1996 through March 2008 at Emory Healthcare Hospitals was performed. Outcomes were compared using χ(2) tests and 2-sample t tests. Adjusted long-term survival up to 10 years was assessed with Kaplan-Meier plots and compared between biologic and mechanical replacements using the Cox proportional hazards model. A total of 202 patients underwent 211 valve replacement operations. Patient age was 20 to 83 years (mean age, 54.8 ± 14.0); 115 of 211 (54.5%) were male. Operations included the following: 100 of 211 (47.4%) isolated aortic; 49 of 211 (23.2%) isolated mitral; 4 of 211 (1.9%) isolated tricuspid; and 58 of 211 (27.5%) combined replacements. Thirteen (6.2%) patients underwent reoperative valve replacements. Most patients received bioprosthetic valves (143 of 211, 67.8%), while 68 of 211 (32.2%) received mechanical valves. Concomitant coronary artery bypass was performed in 53 of 211 (25.1%) patients. Thirty-day mortality was in 42 of 211 patients (19.9%) and was not different between bioprosthetic and mechanical replacements. Overall 10-year survival was 18.1% for all patients and was not influenced by valve type implanted. For patients with end-stage renal disease treated with dialysis, valve replacement carries acceptable operative mortality. Long-term survival is similar among patients receiving bioprosthetic versus mechanical valve replacement. Careful risk assessment and choice of valve prosthesis should be performed prior to surgical intervention in this high-risk patient population.
    The Annals of thoracic surgery 02/2011; 91(4):1127-34. · 3.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There is conflicting evidence guiding valve prosthesis selection in patients with end-stage renal disease on dialysis. We sought to determine, after reviewing the relevant literature, the best valve substitute in patients on chronic dialysis. A total of 9 retrospective studies compared the outcomes of two valves, showing similar results and highlighting the safety of implanting bioprostheses in patients on chronic dialysis. Standards of valve selection have changed over time; it has long been believed that tissue valves undergo premature degeneration due to calcium metabolism derangements in patients with end-stage renal disease. Bleeding was the most common valve-related complication and represented a major drawback of mechanical valves. Two studies demonstrated a survival advantage in favour of mechanical prostheses. It can be concluded that surgeons should not hesitate to implant bioprostheses because singular valve decomposition would be uncommon in this patient population. Prosthesis selection should be based on the same criteria as those used for non-dialysis patients.
    Sultan Qaboos University medical journal 11/2013; 13(4):581-584.
  • [Show abstract] [Hide abstract]
    ABSTRACT: A beam of neutrons with an identical and well-known wavelength was produced by Bragg reflection in a perfect silicon crystal; the velocity of the neutrons was measured using a very precise time-of-flight method. According to the de Broglie equation, the product of these two quantities is equal to the quotient h/m<sub>n</sub> (h Planck constant, m<sub>n</sub> neutron mass). The result is h/m<sub>n</sub>=3 956 033 320(302)×10<sup>7</sup> m<sup>2</sup> s<sup>-1</sup> (relative uncertainty: 7.7×10<sup>-8</sup>). From this value, a value of the fine-structure constant α was derived, leading to α<sup>-1 </sup>=137 036 011 28(5 24) (relative uncertainty: 3.9×10<sup>-8 </sup>). The experiment was carried out at the high-flux reactor of the Institut Laue-Langevin in Grenoble, France
    IEEE Transactions on Instrumentation and Measurement 05/1995; · 1.71 Impact Factor

Full-text (2 Sources)

Available from
May 15, 2014